Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Banner Pharmacaps has announced that the FDA has granted approval for its abbreviated new drug application for nimodipine 30mg soft gelatin capsules.
Subscribe to our email newsletter
Banner’s nimodipine 30mg capsules are the AB-rated generic equivalent of Bayer’s Nimotop 30mg capsules, and are indicated for the treatment of subarachnoid hemorrhage, a form of cerebral bleed and can be dispensed either in blister packaging or in bottles.
Banner has partnered with Heritage Pharmaceuticals, a New Jersey-based generics company, for the exclusive US sales and marketing rights.